loading page

Functional Consequence and Therapeutic Targeting of Cryptic ALK Fusions (ALK fus ) in Monosomy7 AML
  • +4
  • Makia K. Manselle,
  • Rhonda E. Ries,
  • Tiffany Hylkema,
  • Amanda Leonti,
  • Danielle C. Kirkey,
  • Scott Furlan ,
  • Soheil Meshinchi
Makia K. Manselle
Fred Hutchinson Cancer Research Center

Corresponding Author:mmansell@fredhutch.org

Author Profile
Rhonda E. Ries
Fred Hutchinson Cancer Research Center
Author Profile
Tiffany Hylkema
Fred Hutchinson Cancer Research Center
Author Profile
Amanda Leonti
Fred Hutchinson Cancer Research Center
Author Profile
Danielle C. Kirkey
Fred Hutchinson Cancer Research Center
Author Profile
Scott Furlan
Fred Hutchinson Cancer Research Center
Author Profile
Soheil Meshinchi
Fred Hutchinson Cancer Research Center
Author Profile

Abstract

Acute Myeloid Leukemia (AML) patients have a wide array of cytogenetic and molecular aberrations which can influence response to therapy. Monosomy7 (Mono7) is a rare subset within pediatric AML (prevalence of 4-5%), that is highly associated with poor outcomes. Fusions involving the ALK gene (14.3%) were exclusively identified within this high-risk cohort while absent across all other AML. Given the dismal outcomes of Mono7, we evaluated the use of crizotinib, an FDA-approved tyrosine kinase inhibitor, used to treat patients with ALK fusions. Our findings suggest that crizotinib may serve as a novel therapy for these patients.
01 Sep 2022Submission Checks Completed
01 Sep 2022Assigned to Editor
01 Sep 2022Submitted to Pediatric Blood & Cancer
07 Sep 2022Reviewer(s) Assigned
11 Oct 2022Review(s) Completed, Editorial Evaluation Pending
11 Oct 2022Editorial Decision: Revise Minor
01 Dec 2022Submission Checks Completed
01 Dec 2022Assigned to Editor
01 Dec 20221st Revision Received
01 Dec 2022Review(s) Completed, Editorial Evaluation Pending
01 Dec 2022Reviewer(s) Assigned
05 Nov 2021Published in Blood volume 138 issue Supplement 1 on pages 2357-2357. 10.1182/blood-2021-148179